Dr. Navin Khanna

Dr Navin Khanna is a molecular biologist with over thirty years of experience in translational research. He retired as Arturo Falaschi Emeritus Scientist from the International Centre for Genetic Engineering and Biotechnology (ICGEB) New Delhi, in December 2022

The “know-how” developed by his team at ICGEB has resulted in the successful commercialization of over 20 diagnostic kits, including point-of-care tests for viral infections like Dengue, HIV, HCV, and HBV. The World Health Organization purchases these highly affordable and high-performing diagnostic kits for their programs in several developing countries

During his stay at ICGEB, his team’s research outcome has resulted in the signing of 2 exclusive commercial agreements between ICGEB and Sun Pharma for the clinical development of the world’s first botanical drug against dengue and a yeast-based dengue subunit vaccine candidate for global use

Dr Khanna is a recipient of several awards and honours, including the Anjani Mashelkar innovation award, the Organization of Pharmaceutical Producers of India’s Scientist Award, the Om Prakash Bhasin Foundation Award, the Ranbaxy Research Award, the Biotech Commercialization Award of the Department of Bioecology, and VASVIK Industrial Research Award. Dr Khanna was honoured with “Padma Shri”, the fourth-highest civilian award in the Republic of India, for his continued translational research efforts

Dr Khanna is a Fellow of all 3 Science Academies of India. He is an adjunct professor at the School of Medicine, Emory University, Atlanta, USA, an adjunct faculty at Translational Health and Technology Institute, Faridabad and an adjunct professor at the Institute of Advanced Virology, Kerala, India. He has been a research council advisor to several national institutes. Dr Khanna is a member of India’s National Technical Advisory Group on Immunizations

Dr Khanna’s current interests remain focussed on the development of a safe, affordable, and effective dengue vaccine

‍